Zealand Pharma A/S · OMXCOP:ZEAL
Zealand Pharma A/S — Q3 2026 Earnings Presentation
17 slides from Zealand Pharma A/S's earnings presentation, Nov 12, 2026
Slide 1: Zealand Pharma Q3 2026 Presentation
Zealand Pharma Transforming metabolic health so millions can live without limits Q3 2026 Presentation November 12, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda Q&A Opening remarks Research Development Financials pipeline Adam Steensberg Utpal Singh David Kendall Henriette Wennicke Chief Executive Chief Scientific Chief Medical Chief Financial Officer Officer Officer Officer 3
Slide 4: Defining progress across the pipeline while building the platform for next-generation medicine creation
Opening remarks Defining progress across the pipeline while building the platform for next-generation medicine creation NON-EXHAUSTIVE Update since Q2 Petrelintidea Survodutideb Building the pipeline (amylin analog) (GCGR/GLP-1R) of the future ✓ Results from Ph2 ZUPREME-1 ✓ Results from Ph3 obesity
Slide 5: On a clear path to sustainable value creation
Opening remarks On a clear path to sustainable value creation METABOLIC FRONTIER 2030 5 launches 10+ clinical programs #1 in idea-to-clinic cycle times Four late-stage assets Fuel the pipeline & build Metabolic health champion Two partnered, two to be licensed commercial capability PARTNERED | OBESI
Slide 6: Strategic investments add new modalities to proven peptide expertise
Research Strategic investments add new modalities to proven peptide expertise Dec 2025 Nov 2026 Peptide-based company Multi-modality metabolic health company STRATEGIC INVESTMENTS 25+ years of metabolic health R&D >10 candidates in the clinic ✓ Oral small molecules Copenhagen Copenhagen Cambridge, M
Slide 7: Clinical pipeline to deliver 5+ launches by 2030
R&D pipeline Clinical pipeline to deliver 5+ launches by 2030 INDICATION PRODUCT CANDIDATE a PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATION LAUNCH BY 2030 COMMERCIAL VALUE Petrelintideb Obesity +/- T2D amylin analog 50% of net Obesity +/- T2D Petrelintide/enicepatideb Q4 2026 profits amylin/GLP-1
Slide 8: Petrelintide: the ideal first choice for chronic weight management
R&D pipeline Petrelintide: the ideal first choice for chronic weight management: easy to start and easy to stay on Phase 2: double-digit weight loss with favorable tolerability Petrelintide clinical development plan Indication Ph 1 Ph 2 Ph 3 Status ZUPREME-11 ZUPREME-22 OW/OB without T2D OW/OB + T2D
Slide 9: Survodutide: strong metabolic profile reinforced in Phase 3
R&D pipeline Survodutide: strong metabolic profile reinforced in Phase 3, with targeted fat loss + muscle preservation BI moving forward with global regulatory submissions in obesity in 2027 Obesity is a complex chronic disease with interconnected SYNCHRONIZE showed survodutide’s potential to target
Slide 10: Broader evidence, broader opportunity: Boehringer Ingelheim deepens investments in survodutide
R&D pipeline Broader evidence, broader opportunity: Boehringer Ingelheim deepens investments in survodutide LIVERAGE results expected in 2027 to support expansion into MASH Where we are: The SYNCHRONIZE program Where we are heading: From the first Phase 3 readouts to the full metabolic picture1-6 MA
Slide 11: Zeydovio (glepaglutide) received a positive CHMP opinion
R&D pipeline ZeydovioTM (glepaglutide) received a positive CHMP opinion with final EC decision expected in Q4 2026 First major advance in SBS treatment in Europe in over a decade Simplified administration and strong efficacy in Phase 3 Lucrative commercial opportunity First and only ready-to-use GLP
Slide 12: ZP9830 is positioned to address large therapeutic opportunities across 80+ autoimmune diseases
R&D pipeline ZP9830 is positioned to address large therapeutic opportunities across 80+ autoimmune diseases A novel Kv1.3 ion channel blocker with pipeline-in-a-product opportunity DEVELOPMENT PROGRAM PROGRESSING RAPIDLY HOW IT WORKS AND WHY IT MATTERS Phase 1b under way; Phase 2 in a second ZP9830
Slide 13: Profit of DKK 3.5 billion in Q3 YTD 2026 driven by the Roche collaboration
Financials Profit of DKK 3.5 billion in Q3 YTD 2026 driven by the Roche collaboration DKK million Q3 YTD 2026 Q3 YTD 2025 P&L reflecting strategic investments in differentiated R&D assets and organization Revenue 4,529 9,146 Gross profit 4,529 9,145 Q3 2026 YTD OPEX compositiona DKK million Research
Slide 14: Strong balance sheet enabling investments into future growth opportunities
Financials Strong balance sheet enabling investments into future growth opportunities 18000 Executing on key strategic priorities and more 16000 15,109 1. Maximize the value of petrelintide ~2,640 -1,561 13,509 ✓ Mono: Phase 2 finished; Phase 3 initiated 34 14000 324 -1,195 ✓ Combo: Phase 2 ZYNERGY
Slide 15: 2026 financial outlook for OPEX has been narrowed reflecting prudent cost control
Financials 2026 financial outlook for OPEX has been narrowed reflecting prudent cost control DKK billion 2026 Guidance as of 2026 Guidance as of 2025 November 12, 2026 May 7, 2026 Actuals Collaboration revenue 4.5 4.5 9.2 Operating expenses excl. OOIa 2.7–3.0 2.7–3.3 2.1 aOperating expenses consist
Slide 16: On a clear path to sustainable value creation
Concluding remarks On a clear path to sustainable value creation Becoming a metabolic health champion Metabolic health Building on champion Partnerships Metabolic Frontier Bringing medicines to millions 2030 Milestones & royalties Sustainable revenue and Leading metabolic health earnings growth 5 la
Slide 17: Q&A
Q&A Zealand Pharma upcoming investor conferences • Jefferies Healthcare Conference, London, November 16-17 • DNB Carnegie Healthcare Conference, Oslo, November 24 • Citi Global Healthcare Conference, Miami, December 1 • J.P. Morgan Healthcare Conference, San Francisco, January 11-14 17